Understanding the prognosis of cerebral small vessel disease
Official title: Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)
Run by Insel Gruppe AG, University Hospital Bern · NCT05734378 · Data updated 2026-11-12
This study looks at how different types of cerebral small vessel disease affect the health and future outcomes of patients, including issues like bleeding in the brain and memory problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 900 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | December 1, 2020 |
| Main results expected | November 30, 2030 |
| Study ends | November 30, 2030 |
| Registry record updated | March 8, 2023 |
| Trial ID | NCT05734378 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with symptomatic cerebral small vessel disease, including those with hypertensive arteriopathy or cerebral amyloid angiopathy.
✕Probably not a fit
Patients with a life expectancy of less than six months due to non-SVD related causes will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to assess the prognosis of patients with cerebral small vessel disease (SVD) by examining the risk of various outcome events based on the type of SVD and its initial presentation. It includes patients with conditions such as hypertensive deep perforator arteriolopathy and cerebral amyloid angiopathy, focusing on symptomatic manifestations like intracerebral hemorrhage and cognitive impairment. The study will follow these patients over time to gather data on their health outcomes.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the prognosis of different types of cerebral small vessel disease, leading to better management strategies for affected patients.
How similar studies have gone: While there have been studies on cerebral small vessel disease, this specific approach focusing on prognosis based on index presentation is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II) * Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2) * Other SVD (i.e. CADASIL or other sporadic or genetic SVD) Exclusion Criteria: * Life expectancy of \<6 months due to not-SVD related causes (i.e. cancer) * Patient is unlikely to attend follow-up visits
Where it's running
-
Department of Neurology, Inselspital Bern University Hospital
Bern, Switzerland Recruiting
Study contacts
- Principal investigator: David J Seiffge, Prof, MD — Department of Neurology, Inselspital Bern University Hospital
- Study coordinator: Marianne Kormann
- Email: studien.stroke@insel.ch
- Phone: +41 31 632 70 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of the Mediterranean Diet on patients with CADASIL and Cerebral Amyloid Angiopathy
This study is testing whether following the Mediterranean Diet can help people with CADASIL and Cerebral Amyloid Angiopathy feel better and reduce their risk of strokes and cognitive decline.
-
Long-term follow-up of Korean CADASIL patients
This 10-year project will track symptoms, brain scans, cognitive tests, and genetic data in about 500 Korean adults with CADASIL to see how the disease progresses.
-
Nitrate-rich beetroot juice to improve brain blood-flow control in cognitive decline
This test gives nitrate-rich beetroot juice or a placebo to people with small vessel cerebrovascular disease or diabetes to see if it improves brain blood-flow regulation and thinking skills.
-
Jiedu Huayu oral medicine for brain hemorrhage due to cerebral amyloid angiopathy
This trial tests a traditional Chinese medicine oral prescription against placebo to see if it can reduce recurrent vascular events in patients with cerebral amyloid angiopathy-related intracerebral hemorrhage.
-
Colchicine to prevent repeat lobar brain bleeds from cerebral amyloid angiopathy
This trial will test whether taking a daily low-dose colchicine pill for a year is safe and helps prevent repeat lobar intracerebral hemorrhage in people with cerebral amyloid angiopathy who are at high risk of another bleed.
-
Analyzing genetic and imaging features in CADASIL patients
This study is trying to see how genetic and brain imaging information can help doctors better understand and treat CADASIL in patients with specific genetic markers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.